Cryoport Q1 Revenue Beats, Guidance Raised as CGT Momentum Builds

What happened

Cryoport reported Q1 2026 revenue of $47.8 million, up 16% year-over-year, driven by 26% growth in commercial cell and gene therapy revenue to $9.1 million and broad-based gains in both Life Sciences Services (+18%) and Products (+15%). The company now supports 766 global clinical trials and 21 commercially approved CGTs, up from 745 and 19 respectively at September 2025. Management raised full-year revenue guidance to $192–196 million from the prior $170–174 million range, signaling stronger-than-expected momentum. Despite these positive trends, the company remains unprofitable on a GAAP basis, and adjusted EBITDA was likely still negative given prior quarters. The raised guidance reflects improving pipeline conversion and successful restructuring, but the path to sustained profitability remains unproven.

Implication

The Q1 beat and guidance raise indicate that Cryoport's restructuring and focus on commercial CGT are gaining traction. Revenue growth is broadening across segments, and the pipeline of clinical trials and approved therapies is expanding. However, the company still burns cash and has negative interest coverage, so valuation depends on future profitability. The raised guidance suggests management sees a clearer path, but execution risk remains high. Investors should watch for sustained positive free cash flow and further commercial therapy approvals before treating this as a compounder. The stock's ~25% rebound already reflects optimism, leaving limited margin of safety at current levels.

Thesis delta

The Q1 2026 results and raised guidance modestly strengthen the bull case by showing accelerating revenue growth and better pipeline metrics. However, the company remains loss-making, and the master report's WAIT stance is still appropriate until profitability and cash flow turn positive. The positive surprise does not yet invalidate the thesis that risk/reward is speculative; it merely delays the need for a downgrade.